Innate Pharma discontinued its Phase 1/2 NK cell engager IPH6501 in B-cell non-Hodgkin lymphoma as part of a strategic pipeline refocus. The company ended the dose-escalation portion previously and said trial data would be presented later, but it will no longer pursue the program under its current plan. Innate described the discontinuation as prioritization toward higher-value assets, including its Nectin-4-targeting ADC IPH4502 in Phase 1 and its progression toward a Phase 3 program for lacutamab in Sézary syndrome. The announcement follows earlier pipeline recalibrations and reinforces the pattern of cost discipline in antibody-heavy immuno-oncology portfolios when program differentiation or commercial priority does not meet internal thresholds. For the market, the decision narrows the near-term opportunity set for NK engager investors and places more emphasis on Innate’s ADC and KIR3DL2-directed programs as the key catalysts.